What is ALLO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.31B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ALLO?

P/E (TTM) is n/a and 52-week range is $0.98 to $4.46 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ALLO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ALLO?

The company profile lists revenue (TTM) near $5M, net income (TTM) near -$4.48B, EPS (TTM) near -$0.49 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Allogene Therapeutics, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 345.5M shares outstanding, ISIN US0197701065 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Allogene Therapeutics, Inc.

$ALLO

Health Care · Biotechnology

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 150 full-time employees. The company went IPO on 2018-10-11. The firm is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The company is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). The company is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Employees

150

Website

allogene.com/

IPO

2018-10-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US0197701065

Headquarters

South San Francisco, California, US

Shares outstanding

345.5M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

73.46%

Browse other companiesFree AI scores and summaries for more stocks